{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:16:59Z","timestamp":1761895019615,"version":"build-2065373602"},"reference-count":11,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,1,13]],"date-time":"2010-01-13T00:00:00Z","timestamp":1263340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:p>\n                    The objective of this Phase 4, open\u2010label, multicentre, observational study was to fulfil food and drug administration (FDA) postapproval requirement to evaluate in healthcare practices the risk of insulin\u2010induced severe hypoglycaemia following initiation of pramlintide therapy in\n                    <jats:italic>N<\/jats:italic>\n                    = 1297 patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) with inadequate glycaemic control. The duration of the study was approximately 6 months. During the adjustment period (0\u20133 months), the incidence and event rate of patient\u2010ascertained severe hypoglycaemia (PASH) were 4.8% and 0.33 events\/patient\u2010year in patients with T1DM and 2.8% and 0.19 events\/patient\u2010year in patients with T2DM. During the maintenance period (&gt;3\u20136 months), the incidence and event rate of PASH declined in patients with T1DM or T2DM. This study confirms that in healthcare practices, the risk of insulin\u2010induced severe hypoglycaemia following the initiation of pramlintide is low in patients with T1DM or T2DM.\n                  <\/jats:p>","DOI":"10.1111\/j.1463-1326.2010.01201.x","type":"journal-article","created":{"date-parts":[[2010,1,13]],"date-time":"2010-01-13T01:05:59Z","timestamp":1263344759000},"page":"548-551","source":"Crossref","is-referenced-by-count":19,"title":["Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study"],"prefix":"10.1111","volume":"12","author":[{"given":"R.","family":"Pencek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Roddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. B.","family":"De Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Meller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,4,20]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"Amylin Pharmaceuticals Inc.San Diego CA: Amylin Pharmaceuticals Inc. 2008."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.4.724"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/15209150252924094"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.2006.2.3.203"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0042"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2006.0013"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.4.1176"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1210\/jcem-65-1-30","article-title":"Effects of age, duration and treatment of insulin\u2010dependent diabetes mellitus on residual beta\u2010cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT)","volume":"65","author":"DCCT Research Group","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1991.tb01575.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.17.7.697"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1993.tb00051.x"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2010.01201.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2010.01201.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:54:31Z","timestamp":1761882871000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2010.01201.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,20]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1463-1326.2010.01201.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01201.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"type":"print","value":"1462-8902"},{"type":"electronic","value":"1463-1326"}],"subject":[],"published":{"date-parts":[[2010,4,20]]}}}